- Home
- PHGE vs DKI Comparison
PHGE vs DKI Comparison
Compare PHGE & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- DKI
- Stock Information
- Founded
- PHGE 2015
- DKI 2018
- Country
- PHGE Israel
- DKI Hong Kong
- Employees
- PHGE N/A
- DKI N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- DKI
- Sector
- PHGE Health Care
- DKI
- Exchange
- PHGE Nasdaq
- DKI Nasdaq
- Market Cap
- PHGE 13.0M
- DKI 11.9M
- IPO Year
- PHGE N/A
- DKI 2025
- Fundamental
- Price
- PHGE $0.31
- DKI $0.45
- Analyst Decision
- PHGE Strong Buy
- DKI
- Analyst Count
- PHGE 1
- DKI 0
- Target Price
- PHGE $15.00
- DKI N/A
- AVG Volume (30 Days)
- PHGE 1.7M
- DKI 220.8K
- Earning Date
- PHGE 11-12-2025
- DKI 11-28-2025
- Dividend Yield
- PHGE N/A
- DKI N/A
- EPS Growth
- PHGE N/A
- DKI N/A
- EPS
- PHGE N/A
- DKI 26.19
- Revenue
- PHGE N/A
- DKI $10,204,329.00
- Revenue This Year
- PHGE N/A
- DKI N/A
- Revenue Next Year
- PHGE N/A
- DKI N/A
- P/E Ratio
- PHGE N/A
- DKI $0.02
- Revenue Growth
- PHGE N/A
- DKI 100.46
- 52 Week Low
- PHGE $0.31
- DKI $0.43
- 52 Week High
- PHGE $1.16
- DKI $15.00
- Technical
- Relative Strength Index (RSI)
- PHGE 27.31
- DKI N/A
- Support Level
- PHGE $0.35
- DKI N/A
- Resistance Level
- PHGE $0.42
- DKI N/A
- Average True Range (ATR)
- PHGE 0.04
- DKI 0.00
- MACD
- PHGE -0.01
- DKI 0.00
- Stochastic Oscillator
- PHGE 2.81
- DKI 0.00
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.